Investor Overview Press Releases January 2, 2019 Aclaris Therapeutics to Attend Upcoming Investor Conferences December 17, 2018 Aclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials December 3, 2018 Aclaris Therapeutics Closes Acquisition of RHOFADE® (oxymetazoline hydrochloride) cream, 1% from Allergan View all » Events Feb 27, 2019 Aclaris Therapeutics, Inc. at 8th Annual Leerink Partners Global Healthcare Conference Jan 7 - Jan 9, 2019 Aclaris Therapeutics, Inc. at 2019 JP Morgan Healthcare Conference Dec 17, 20185:00 PM EST Aclaris Therapeutics Provides R&D Update on ATI-501 and ATI-502 Programs View all » Feature presentation Aclaris Therapeutics Company Overview
December 17, 2018 Aclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials
December 3, 2018 Aclaris Therapeutics Closes Acquisition of RHOFADE® (oxymetazoline hydrochloride) cream, 1% from Allergan
